Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Madrigal Pharmaceuticals (MDGL) Total Non-Current Liabilities (2019 - 2025)

Madrigal Pharmaceuticals (MDGL) has disclosed Total Non-Current Liabilities for 13 consecutive years, with $346.6 million as the latest value for Q4 2025.

  • On a quarterly basis, Total Non-Current Liabilities rose 192.28% to $346.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $346.6 million, a 192.28% increase, with the full-year FY2025 number at $346.6 million, up 192.28% from a year prior.
  • Total Non-Current Liabilities was $346.6 million for Q4 2025 at Madrigal Pharmaceuticals, roughly flat from $345.3 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $346.6 million in Q4 2025 to a low of $283000.0 in Q1 2022.
  • A 5-year average of $98.5 million and a median of $107.6 million in 2023 define the central range for Total Non-Current Liabilities.
  • Peak YoY movement for Total Non-Current Liabilities: fell 26.87% in 2022, then soared 29569.61% in 2023.
  • Madrigal Pharmaceuticals' Total Non-Current Liabilities stood at $387000.0 in 2021, then surged by 12636.18% to $49.3 million in 2022, then surged by 136.7% to $116.7 million in 2023, then increased by 1.65% to $118.6 million in 2024, then skyrocketed by 192.28% to $346.6 million in 2025.
  • Per Business Quant, the three most recent readings for MDGL's Total Non-Current Liabilities are $346.6 million (Q4 2025), $345.3 million (Q3 2025), and $122.9 million (Q2 2025).